UNH raised guidance, but the value thesis still depends on earnings quality

UnitedHealth reported Q2 revenue of $112.0 billion, operating earnings of $8.0 billion and adjusted EPS of $6.38. Management also raised full-year adjusted EPS guidance to $19.50-$20.00.

The headline is clearly better. I am less convinced that one strong quarter is enough to declare the value thesis fully repaired.

Three things matter to me from here:

1. Cash conversion

Operating cash flow was $11.1 billion, or 1.9x net income. That is encouraging, but the question is whether strong cash conversion persists as medical costs, working capital and claims timing normalize.

2. Source of margin recovery

A durable recovery should come from better pricing, cost control and operating execution across UnitedHealthcare and Optum. If improvement depends mainly on favorable timing or temporary utilization patterns, the normalized earnings base may be lower than the headline suggests.

3. Balance sheet and capital allocation

Debt-to-capital was 41.2%. That is manageable for a business of this scale, but buybacks and acquisitions create the most value only if management has correctly identified normalized earnings power.

My takeaway: the quarter reduces the probability that the business is structurally broken. It does not eliminate the risk that investors are capitalizing a rebound before its durability is proven.

For a value investor, the key question is not whether UNH beat this quarter. It is what level of earnings and free cash flow can be underwritten through a full medical-cost cycle.

Official results: https://www.unitedhealthgroup.com/newsroom/2026/2026-07-16-uhg-reports-second-quarter-2026-results.html

What would you need to see over the next two quarters before treating the recovery as durable?